

UNITED STATES  
PATENT AND  
TRADEMARK OFFICECommissioner for Patents  
Washington, DC 20231  
www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/961,381	09/25/2001	Gary Lynch	1819.0040001/MAC/LBB

CONFIRMATION NO. 7154

FORMALITIES LETTER



\*OC000000009794755\*

26111  
STERNE, KESSLER, GOLDSTEIN & FOX PLLC  
1100 NEW YORK AVENUE, N.W.  
WASHINGTON, DC 20005

Date Mailed: 04/08/2003

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES***Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice MUST be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LYNCH *et al.*

Appl. No. 09/961,381

Filed: September 25, 2001

For: **Model for Neurodegenerative  
Diseases Involving Amyloid  
Accumulation**

Confirmation No. 7154

Art Unit: 1645

Examiner: *To be assigned*

Atty. Docket: 1819.0040001/MAC/LBB

**Letter**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated April 8, 2003, Applicants submit a copy of the disk originally submitted on March 26, 2003.

In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing previously submitted on March 26, 2003 and the computer readable copy of the Sequence Listing submitted herewith in the above application are the same.

It is respectfully believed that this application is now in condition for examination. Early notice of this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Lawrence B. Bugaisky  
Attorney for Applicants  
Registration No. 35,086

Date: April 22, 2003

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

ODMA MHODMA SKGF\_DC1.126291.1  
SKGF rev 1.26.01 mac

Sterne Kessler  
Goldstein Fox



Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
David S. Fox  
Robert A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Robert J. Kessler  
Joseph A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Steven R. Goldstein  
Joseph A. Goldstein  
David S. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
Michael A. Goldstein  
Michael B. Fox

Joseph A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
David S. Fox  
Robert A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Steven R. Goldstein  
Joseph A. Goldstein  
David S. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
Michael A. Goldstein  
Michael B. Fox

Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
David S. Fox  
Robert A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
David S. Fox  
Robert A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Steven R. Goldstein  
Joseph A. Goldstein  
David S. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
Michael A. Goldstein  
Michael B. Fox

Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
David S. Fox  
Robert A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
David S. Fox  
Robert A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Steven R. Goldstein  
Joseph A. Goldstein  
David S. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
Michael A. Goldstein  
Michael B. Fox

Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
David S. Fox  
Robert A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
David S. Fox  
Robert A. Goldstein  
Michael A. Goldstein  
Michael B. Fox  
Steven R. Goldstein  
Joseph A. Goldstein  
David S. Fox  
Robert J. Kessler  
Edward J. Kessler  
Joseph A. Goldstein  
Michael A. Goldstein  
Michael B. Fox

April 22, 2003

WRITER'S DIRECT NUMBER:

(202) 772-8589

INTERNET ADDRESS:

LARRYB@SKGF.COM

Commissioner for Patents  
Washington, D.C. 20231

Art Unit 1645

Re: U.S. Patent Application  
Appl. No. 09/961,381; Filed: September 25, 2001  
For: **Model for Neurodegenerative Diseases Involving Amyloid Accumulation**  
Inventors: Lynch *et al.*  
Our Ref: 1819.0040001/MAC/LBB

Sir:

Transmitted herewith for appropriate action are the following documents:

1. SKGF Cover Letter;
2. Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
3. Letter;
4. Disk copy of Sequence Listing; and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
April 22, 2003  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lawrence B. Bugaisky  
Attorney for Applicants  
Registration No. 35,086

LBB/ybh  
Enclosures

ODMA MHODMA SKGF\_DC1:126266;1  
SKGF Rev. 2 15 02 dew